Skip to content
Screener

Operating Cash Flow at other companies

TFX
TeleflexTFX
$91.9M+348%
Boston Scientific logo
Boston ScientificBSX
$348M-35.7%
Intuitive Surgical logo
Intuitive SurgicalISRG
$1.06B+48.3%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
-$572K+18.5%
PDE
Pro-Dex, Inc.PDEX
$1.63M+488%
Microbot Medical logo
Microbot MedicalMBOT
-$5.05M-75.8%

Other financials

Income statement

See full
Revenue$94.5M+19.3%
Gross profit$62.4M+20.5%
Operating income-$27.4M-23.4%
Net income-$26.9M-37.2%
EPS (diluted)-$0.47-34.3%

Balance sheet

See full
Cash & equivalents$11.4M-96.3%
Total debt$77.5M-2.4%
Total equity$340.1M-11.9%
Total assets$479.4M-6.6%

Cash flow

See full
CapEx$3.0M+5.4%
Free cash flow-$22.2M-24.4%

Valuation

See full
Market cap$1.15B-25.9%
Enterprise value$1.21B
P/S3.4×

Profitability

See full
Gross margin64.2%0.0pp
Operating margin-33.9%+0.5pp
Net margin-32.5%+2.2pp
FCF margin-25.2%-4.6pp

Returns & leverage

See full
Return on equity-30.2%+5.2pp
Debt / equity0.2×0.0×
Current ratio6.5×-2.7×

Where this comes from

Reported directly by PROCEPT BioRobotics Corporation in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: PROCEPT BioRobotics Corporation’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001588978-26-000030
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Loan facility liability(2,000)
Deferred revenue984223
Other liabilities1,9711,561
Net cash used in operating activities(57,378)(32,023)
Cash flows from investing activities:
Purchases of property and equipment(5,867)(4,638)
Net cash used in investing activities(5,867)(4,638)
Cash flows from financing activities:

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is PROCEPT BioRobotics Corporation's operating cash flow?
PROCEPT BioRobotics Corporation (PRCT) reported operating cash flow of -$19.25M in Q2 2026.
How has PROCEPT BioRobotics Corporation's operating cash flow changed year-over-year?
PROCEPT BioRobotics Corporation's operating cash flow decreased by 28.0% year-over-year, from -$15.04M to -$19.25M.
What is the long-term trend for PROCEPT BioRobotics Corporation's operating cash flow?
Over 4 years (2021 to 2025), PROCEPT BioRobotics Corporation's operating cash flow has grown at a -3.9% compound annual growth rate (CAGR), from -$57.33M to -$48.99M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about PROCEPT BioRobotics Corporation's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude